Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUCOURSE: Mirogabalin in Asian patients with post-herpetic neuralgia
NCT02318719Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirogabalin in postherpetic neuralgia (PHN) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Average Daily Pain Score at 14 weeks. Started Jan 2015; status: completed.
02
Drugs
mirogabalin
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT02318719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318719.